drugset / Trial / NCT06504290

Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119

NCT06504290

Phase 1 Recruiting 40 enrolled Vigonvita Life Sciences
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will consist of 2 parts: Part Ⅰ-in healthy adult subjects, Part Ⅱ-in adult patients with schizophrenia

Timeline

Start
2024-07-16
Primary completion
2026-07-01
Completion
2026-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject VV119 Unknown 0.5 mg Oral
Subject VV119 Unknown 1 mg Oral
Subject VV119 Unknown 2 mg Oral
Subject VV119 Unknown 4 mg Oral
Subject VV119 Unknown 6 mg Oral

Indications